Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)

Clinical trial NCT07362199 · RECRUITING

Trial details

NCT number: NCT07362199
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Immune Thrombocytopenia Treatment

Start date: 2026-03-01
Primary completion: 2027-03-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.